Pieris Pharmaceuticals Inc (PIRS)

NASDAQ
5.620
+0.180(+3.31%)
After Hours
5.700
+0.080(+1.423%)
- Real-time Data
  • Volume:
    3,322,946
  • Bid/Ask:
    5.700/5.900
  • Day's Range:
    5.448 - 6.150

PIRS Overview

Prev. Close
5.44
Day's Range
5.448-6.15
Revenue
23.74M
Open
5.46
52 wk Range
1.7-6.15
EPS
-0.84
Volume
3,322,946
Market Cap
374.91M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,267,446
P/E Ratio
-
Beta
1.19
1-Year Change
176.85%
Shares Outstanding
66,710,712
Next Earnings Date
Nov 10, 2021
What is your sentiment on Pieris Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Pieris Pharmaceuticals Inc News

Pieris Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellSellBuyStrong Buy
SummaryStrong SellStrong SellNeutralStrong BuyStrong Buy

Pieris Pharmaceuticals Inc Company Profile

Pieris Pharmaceuticals Inc Company Profile

Employees
111

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Read More
  • Is this stock worth buying at all?
    0
    • Earning today
      0
      • How is this stock in such a slump??
        0
        • Today open 5$
          1
          • 3.37$ isn't good to buy?
            0
            • SHORTING Time! Easy money :)
              0
              • Yeah i hesitate, what's your sell and buy objectif ?
                0
            • hi
              0
              • Price target much higher than where its now. Absolute potential buy.
                0
                • Price target much higher than where its now. Absolute potential buy.
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.